We do not know the exact criteria for selection of patients in the clinical trial.
It COULD be that they are enrolling only those patients who are the most critically ill. Not everyone in the ICU is equally sick.
If they are enrolling only extremely sick patients, then it will be apparent whether Brilacidin treatment makes a difference in death rates. There also could be significant differences in the number of days a person spends in the ICU.
We'll know when we know. I doubt very much whether IPIX would proceed with a clinical trial whose results would be useless. It's perfectly possible to design a clinical trial that will show efficacy or lack thereof.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links